Company

Sonnet BioTherapeutics Holdings, Inc.

Headquarters: Princeton, NJ, United States

Employees: 9

CEO: Dr. Pankaj Mohan Ph.D.

NASDAQ: SONN -0.54%

Market Cap

$4.7 Million

USD as of Jan. 1, 2024

Market Cap History

Sonnet BioTherapeutics Holdings, Inc. market capitalization over time

Evolution of Sonnet BioTherapeutics Holdings, Inc. market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Sonnet BioTherapeutics Holdings, Inc.

Detailed Description

Sonnet BioTherapeutics Holdings, Inc., a clinical stage oncology-focused biotechnology company, develops platform for biologic medicines of single or bispecific action. The company develops fully human albumin binding technology, which utilizes human single chain antibodies fragment that binds to and hitch-hikes on human serum albumin for transport to target tissues. Its lead candidate is SON-1010, a fully human version of interleukin 12 for the treatment non-small cell lung cancer, and head and neck cancer. The company is also developing SON-080, a fully human version of interleukin 6 for chemotherapy-induced peripheral neuropathy and diabetic peripheral neuropathy. It has a license agreement with New Life Therapeutics PTE, LTD. to develop and commercialize pharmaceutical preparations containing a specific recombinant human interleukin 6. Sonnet BioTherapeutics Holdings, Inc. is based in Princeton, New Jersey.

Top 1-year algo backtest: +269.94%

$10,000 in May 2023 would now be $36,994 by following this algorithm daily at market close.

Boost your stocks returns with Disfold AI... Now!

Try Disfold AI for FREE

Stocks & Indices

Sonnet BioTherapeutics Holdings, Inc. has the following listings and related stock indices.


Stock: NASDAQ: SONN wb_incandescent

Stock: FSX: H3D wb_incandescent

Details

Headquarters:

100 Overlook Center

Suite 102

Princeton, NJ 08540

United States

Phone: 609 375 2227